Clinical Insights into Psoriasis in Patients of Color: Bringing New Data to Light

Various gaps in the management of psoriasis in patients with SOC persist due to a lack of training for dermatology practitioners. As a result, patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden. Given the predicted increase in the SOC population over the next decades, improving the diagnosis and management of psoriasis in these patients is critical. To improve outcomes in SOC patients with psoriasis, this webcast features esteemed expert dermatologists Mona Shahriari, MD, and Andrew Alexis, MD, MPH engaging in a conversational, expert discussion providing actionable guidance on the clinical presentation, disease burden, clinical and therapeutic nuances of treatment, and strategies to address barriers to care and individualize treatment plans.

Target Audience

This activity is designed for an audience of physicians, nurses, and other advanced practice providers (nurse practitioners/physician assistants) in medical practices that specialize in dermatology.

Learning Objectives

Upon completion of the educational activity, participants should be better able to:

  • Describe the clinical presentation and disease burden of psoriasis in SOC patients.
  • Summarize clinical updates and nuances of treatment for psoriasis in SOC patients.
  • Implement strategies to address patients’ barriers to care and individualize treatment plans.

You may also be interested in

Infants and Atopic Dermatitis: The Biggest Help for the Smallest Patients

Pediatric patients with skin of color (SOC) face unique challenges in managing AD, including issues with disease associated sequelae. In fact, these patients are more likely to suffer from more severe AD cases.
A New Age in Pediatric Psoriasis: Case-Based Learning for Inclusive Care

Psoriasis is an immune-mediated disease that currently affects more than 8 million Americans and 125 million people worldwide according to the World Psoriasis Day consortium.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
03/29/2024
Course expires: 
03/30/2025
Rating: 
0
  • Defining "Skin of Color" and Epidemiology of Psoriasis
  • Disparities in Care and Clinical Trial Participation
  • Case 1 - Assessing Psoriasis in SOC
  • Case 2 - Facial Psoriasis
  • Case 3 - Scalp Psoriasis
  • Case 4 - Post-Inflammatory Pigment Alteration (PIPA)
  • Case 5 - Culturally Competent Care

 

Andrew Alexis, MD, MPH
Mona Shahriari, MD
Andrew Alexis, MD, MPH
Vice Chair for Diversity and Inclusion
Weill Cornell Medicine
New York, NY
Mona Shahriari, MD
Assistant Clinical Professor of Dermatology
Yale University
New Haven, CT

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

Advancing Knowledge in Healthcare Inc.LiVDerm logo

Joint Accredited Provider Logo In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse

1 ANCC contact hour.

 

Commercial Support

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

 

DISCLOSURES

Name

Relationship

Commercial Interest

Andrew Alexis

Advisory board/Consulting

Leo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdorf, Ortho, L’Oreal, BMS, Bausch health, UCB, Vyne , Arcutis, Janssen, Allergan, Almirall, Abbvie, Amgen, VisualDx, Eli Lilly, Swiss American, Cutera, Cara, EPI, Incyte, Castle, Apogee, Canfield, Alphyn

Researcher

Grants (funds to institution): Leo, Amgen, Galderma, Arcutis, Dermavant, Abbvie, Castle

Royalties or patent beneficiary

Royalties

Speaker

Regeneron, SANOFI-Genzyme, BMS, L’Oreal, Janssen, J&J

Mona Shahriari, MD

Consultant

AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Cara, Dermavant, Incyte, Galderma, Janssen, Leo Pharma, Lilly USA, Novartis, Sanofi-Genzyme, Regeneron, UCB

Researcher

AbbVie, CorEvitas Psoriasis and Atopic Dermatitis Registry, Dermira, Cara, Dermavant, Novartis, Union, Mindera

Speaker

Abbvie, Arcutis, Bristol Myers Squibb, Lilly USA, Janssen, Dermavant, Leo Pharma, Pfizer, Sanofi-Genzyme, Regeneron, UCB

Dorothy Caputo, MA, BSN, RN, VP, Healthcare CE and Operations

N/A

Nothing to disclose

Michele Bielarski, RN (planner/reviewer)

N/A

Nothing to disclose

AKH Inc Staff and Planners

N/A

Nothing to disclose

Tarsus dba LiVDerm Staff and Planners

N/A

Nothing to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.

AKH Privacy Policy (link: https://akhcme.com/akhcme/pages/privacy)

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.